完美世界前传下载,古风小说君子以泽

Phase 1 Clinical Trial in Healthy Subjects in Australia (NCT05653037)

This was a randomized, single-blind, placebo-controlled phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses (“SAD”) of subcutaneously administered RBD4059 in healthy subjects.

Phase 2a Clinical Trial in Patients with Coronary Artery Disease in Sweden (NCT06717074)

This a randomized, double-blind, placebo-controlled phase 2a trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059 in participants with stable coronary artery disease.

Phase 1 Clinical Trial in Healthy Subjects in Australia (NCT05539651)

This was a randomized, double-blind, placebo-controlled phase 1 trial to evaluate the safety, tolerability, PK profiles and PD effect of single and multiple ascending doses (“MAD”) of subcutaneously administered RBD5044 in healthy subjects.

Phase 2 Clinical Trial in Patients with Mixed Dyslipidemia in Sweden (NCT06797401)

This is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group phase2 clinical trial to evaluate the efficacy and safety of RBD5044 subcutaneous injections in participants with mixed dyslipidemia.

Phase 1 Clinical Trial in Participants with Normal or Elevated LDL-c Cholesterol in China (NCT05912296)

This is a randomized, single blind, placebo controlled, single center phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously administered RBD7022 in participants with normal or elevated LDL-c cholesterol.

Phase 1a Clinical Trial in Healthy Subjects in Australia (NCT04685564)

This was a randomized, double-blind, placebo-controlled, single dose-escalation study to observe the safety and PK of RBD1016 in healthy subjects.

Phase 1b Clinical Trial in Patients with CHB in Hong Kong (NCT05017116)

This was a randomized, double-blind, placebo-controlled, single and repeated dose escalation study to evaluate the safety, PK and preliminary pharmacodynamics (PD) of RBD1016 in patients with CHB.

Phase 2a Clinical Trial in CHD Patients in Sweden (NCT06649266)

This is a multi-center, randomized, partially blinded and placebo-controlled phase 2a study to evaluate the safety, efficacy and PK of RBD1016 in patients with CHD.

Phase 2 Global MRCT in CHB Patients (NCT05961098)

This is a multi-national, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the long-term safety and efficacy of RBD1016 on background of Nas in the treatment of CHB.

About Ribo

About Ribo

International R&D Center

Our Story

Leadership Team

Scientific Advisory Board

News

Science

About Oligonucleotide Therapeutics

Technological Innovations

Intellectual Property

Pipeline

Therapeutic Area

Pipeline

Products

Clinical Trials

Collaboration

BD and Collaboration

Careers

Our Culture

Career Development

Recruitment

Contact Information